BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 25110407)

  • 1. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
    Renna S; Cottone M; Orlando A
    World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
    Hanauer SB; Sandborn WJ; Lichtenstein GR
    Gastroenterology; 2019 Jan; 156(1):36-42. PubMed ID: 30195449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate for inflammatory bowel disease: time for reconsideration.
    Nielsen OH; Ainsworth MA; Steenholdt C
    Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
    [No Abstract]   [Full Text] [Related]  

  • 6. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
    Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
    Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert opinion: experience with 6-mercaptopurine in the treatment of inflammatory bowel disease.
    Korelitz BI
    World J Gastroenterol; 2013 May; 19(20):2979-84. PubMed ID: 23716977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory Bowel Disease - Non-biological treatment.
    Magro F; Cordeiro G; Dias AM; Estevinho MM
    Pharmacol Res; 2020 Oct; 160():105075. PubMed ID: 32653651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
    Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
    Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small intestinal bacterial overgrowth in inactive Crohn's disease: influence of thiopurine and biological treatment.
    Sánchez-Montes C; Ortiz V; Bastida G; Rodríguez E; Yago M; Beltrán B; Aguas M; Iborra M; Garrigues V; Ponce J; Nos P
    World J Gastroenterol; 2014 Oct; 20(38):13999-4003. PubMed ID: 25320539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease.
    Nguyen GC; Harris ML; Dassopoulos T
    Curr Gastroenterol Rep; 2006 Dec; 8(6):499-505. PubMed ID: 17105689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
    Kobayashi T; Uda A; Udagawa E; Hibi T
    J Crohns Colitis; 2020 Jun; 14(5):617-623. PubMed ID: 31867632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
    Mao EJ; Hazlewood GS; Kaplan GG; Peyrin-Biroulet L; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2017 Jan; 45(1):3-13. PubMed ID: 27862107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
    Balram B; Lubov J; Theoret Y; Afif W; Bitton A; Wild G; Lakatos PL; Bessissow T
    Dig Dis Sci; 2021 May; 66(5):1650-1657. PubMed ID: 32591969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective.
    Axelrad JE; Roy A; Lawlor G; Korelitz B; Lichtiger S
    World J Gastroenterol; 2016 Dec; 22(46):10103-10117. PubMed ID: 28028358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
    Pariente B; Laharie D
    Aliment Pharmacol Ther; 2014 Aug; 40(4):338-53. PubMed ID: 24957164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.